- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2023 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Osteoporosis
The Endocrinology Network® Osteoporosis clinical resource center is our hub for the latest in bone health and management of fracture risk. With a fracture causing significant increases in risk of mortality, management of osteoporosis represents a crucial aspect of care. This page will offer the latest information related to FDA approvals, new studies, and guideline updates pertaining to diagnosis and management of osteoporosis.
New UK Guidelines Released for Diagnosis, Management of Osteoporosis
April 22, 2022
On April 20, the UK National Osteoporosis Guideline Group released updated guidance for the diagnosis, prevention, and treatment of osteoporosis, which has received endorsements from the IOF and ESCEO.
NSAID Use Could Blunt Benefit of Osteoporosis Medications
April 20, 2022
An analysis of data from a 5000-patient cohort suggests use of NSAIDs was associated with a detrimental effect on the benefit of clodronate on reducing risk of fracture among older women.
High Levels of Body Fat Linked to Increased Osteoporosis Risk in Men
February 10, 2022
Using data from NHANES, researchers at the University of Chicago provide insight into associations of fat mass index and lean mass index on bone mineral density and how sex influences these associations.
Comparing Fracture Risk with Risedronate vs Alendronate During Drug Holidays
January 18, 2022
An analysis of data from more than 50k patients using risedronate or alendronate from Ontario compares the risk of hip fracture and other outcomes during drug holidays.
Endocrine Month in Review: November 2021
November 27, 2021
November's endocrine month in review features stories on the Build Back Better Act, a recent review from the IOF, data from Kidney Week 2021, and more.
International Osteoporosis Foundation Issues Review of Links Between Bone Loss and Vascular Calcification
November 18, 2021
The latest review from the International Osteoporosis Foundation is a 14-page document with more than 100 references outlining current data related to the pathophysiological links between vascular calcification and bone loss.
Endocrine Month in Review: October 2021
October 30, 2021
October's endocrine month in review features stories on the new ADA and EASD type 1 diabetes guidance, a phase 2 trial examining oral PTH tablets for osteoporosis, and a 3-part panel discussion focusing on diabetes management in 2021.
No Increase in Fracture Risk from SGLT2 Inhibitor Use, Study Finds
October 29, 2021
A propensity score-matched analysis comparing fracture risk associated with the initiation of SGLT2 inhibitors versus GLP-1RAs or DPP-4 inhibitors indicates use of SGLT2 inhibitors was not associated with an increase in risk of fractures in older patients with type 2 diabetes.
Patients with Diabetes Remain at Increased Fracture Risk, Despite Declines in Overall Population
October 07, 2021
An analysis of more than 1.2 million patients who experienced a fracture from 1997-2017 provides insight into contemporary trends in fracture incidence rates based on presence of diabetes.